Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY HD-Long: Long-term safety and efficacy of enarodustat in anemic CKD patients on maintenance hemodialysis
jRCT2080223644Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enarodustat in anaemia, chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by Japan Tobacco. Primary endpoint: Long-term safety over 52 weeks. Started Sep 2017; status: completed.
02
Drugs
enarodustat
03
Conditions
anaemiachronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080223644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223644.